Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer
Status:
Terminated
Trial end date:
2017-09-22
Target enrollment:
Participant gender:
Summary
This trial is being performed in two parts: Dose Escalation and Dose Expansion.
The primary objective for the Dose Escalation part is to determine the safety and
tolerability at different doses of DS-8273a administered in combination with nivolumab and to
identify the dose combination for the Dose Expansion cohort in subjects with mismatch repair
(MMR)-proficient advanced colorectal cancer.
The primary objectives for the Dose Expansion part are:
- To further evaluate the safety and tolerability of DS-8273a administered at the selected
dose in combination with nivolumab in subjects with MMR-proficient advanced colorectal
cancer
- To evaluate preliminary anti-tumor activity of DS-8273a plus nivolumab administered at
the selected dose in subjects with MMR-proficient advanced colorectal cancer